Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 714 | 11q13.1 | CAPN1 | calpain 1 | |
Mouse | - | 713 | 19 4.34 cM | Capn1 | calpain 1 | |
Rat | - | 713 | 1q43 | Capn1 | calpain 1 |
Database Links | |
Specialist databases | |
MEROPS | C02.001 (Hs) |
Other databases | |
Alphafold | P07384 (Hs), O35350 (Mm), P97571 (Rn) |
BRENDA | 3.4.22.52 |
ChEMBL Target | CHEMBL3891 (Hs), CHEMBL3747 (Rn) |
Ensembl Gene | ENSG00000014216 (Hs), ENSMUSG00000024942 (Mm), ENSRNOG00000020935 (Rn) |
Entrez Gene | 823 (Hs), 12333 (Mm), 29153 (Rn) |
Human Protein Atlas | ENSG00000014216 (Hs) |
KEGG Enzyme | 3.4.22.52 |
KEGG Gene | hsa:823 (Hs), mmu:12333 (Mm), rno:29153 (Rn) |
OMIM | 114220 (Hs) |
Pharos | P07384 (Hs) |
RefSeq Nucleotide | NM_005186 (Hs), NM_001198869 (Hs), NM_001198868 (Hs), NM_001110504 (Mm), NM_007600 (Mm), NM_019152 (Rn) |
RefSeq Protein | NP_005177 (Hs), NP_001185798 (Hs), NP_001185797 (Hs), NP_001103974 (Mm), NP_031626 (Mm), NP_062025 (Rn) |
UniProtKB | P07384 (Hs), O35350 (Mm), P97571 (Rn) |
Wikipedia | CAPN1 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific inhibitor tables |
Immuno Process Associations | ||
|
||
|
||
|
||
|
1. Adams SE, Parr C, Miller DJ, Allemann RK, Hallett MB. (2012) Potent inhibition of Ca2+-dependent activation of calpain-1 by novel mercaptoacrylates. Medchemcomm, 3: 566 (Concise Article). DOI: 10.1039/C2MD00280A
2. Iqbal M, Messina PA, Freed B, Das M, Chatterjee S, Tripathy R, Ming Tao, Josef KA, Dembofsky B, Dunn D et al.. (1997) Subsite requirements for peptide aldehyde inhibitors of human calpain I. Bioorg Med Chem Lett, 7: 539-544. DOI: 10.1016/S0960-894X(97)00063-2
3. Ovat A, Li ZZ, Hampton CY, Asress SA, Fernández FM, Glass JD, Powers JC. (2010) Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem, 53 (17): 6326-36. [PMID:20690647]
4. Xia Z, Sacco M, Hu Y, Ma C, Meng X, Zhang F, Szeto T, Xiang Y, Chen Y, Wang J. (2021) Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacol Transl Sci, 4 (4): 1408-1421. [PMID:34414360]
C2: Calpain: calpain 1. Last modified on 26/08/2021. Accessed on 14/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336.